Vir Biotechnology (NASDAQ:VIR) was upgraded by Zacks Investment Research from a "sell" rating to a "hold" rating in a research note issued to investors on Thursday, Zacks.com reports.
According to Zacks, "Vir Biotechnology Inc. is a clinical-stage immunology company. It is focused on combining immunologic insights to treat and prevent serious infectious diseases. The company's development pipeline consists of product candidates targeting the hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis. Vir Biotechnology Inc. is based in San Francisco, United States. "
A number of other research firms have also recently commented on VIR. Needham & Company LLC reaffirmed a "buy" rating and set a $80.00 price objective on shares of Vir Biotechnology in a research report on Friday, April 16th. Barclays lifted their price objective on shares of Vir Biotechnology from $61.00 to $77.00 and gave the stock an "overweight" rating in a research report on Thursday, February 25th. HC Wainwright lifted their price objective on shares of Vir Biotechnology from $125.00 to $135.00 and gave the stock a "buy" rating in a research report on Monday, March 8th. Finally, The Goldman Sachs Group lifted their price objective on shares of Vir Biotechnology from $59.00 to $61.00 and gave the stock a "buy" rating in a research report on Wednesday, March 3rd. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of "Hold" and an average target price of $66.00.
NASDAQ VIR opened at $44.45 on Thursday. Vir Biotechnology has a 12-month low of $25.31 and a 12-month high of $141.01. The firm has a market capitalization of $5.78 billion, a P/E ratio of -14.39 and a beta of -1.72. The firm has a 50 day simple moving average of $44.92.
Vir Biotechnology (NASDAQ:VIR) last issued its earnings results on Thursday, May 6th. The company reported ($1.32) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.23) by ($1.09). The firm had revenue of $1.98 million for the quarter, compared to analyst estimates of $170.53 million. Vir Biotechnology had a negative return on equity of 56.90% and a negative net margin of 537.47%. Analysts anticipate that Vir Biotechnology will post -2.86 EPS for the current year.
In related news, Director Vicki L. Sato sold 15,174 shares of the business's stock in a transaction dated Wednesday, May 19th. The stock was sold at an average price of $43.80, for a total value of $664,621.20. Following the completion of the transaction, the director now owns 1,660,782 shares of the company's stock, valued at $72,742,251.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Herbert Virgin sold 7,900 shares of the business's stock in a transaction dated Tuesday, March 23rd. The shares were sold at an average price of $53.60, for a total value of $423,440.00. Following the completion of the transaction, the executive vice president now directly owns 82,100 shares of the company's stock, valued at approximately $4,400,560. The disclosure for this sale can be found here. In the last three months, insiders sold 63,294 shares of company stock valued at $2,893,803. 37.20% of the stock is currently owned by company insiders.
A number of hedge funds have recently bought and sold shares of the stock. Dimensional Fund Advisors LP raised its stake in Vir Biotechnology by 2.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 9,870 shares of the company's stock valued at $264,000 after purchasing an additional 274 shares in the last quarter. Principal Financial Group Inc. raised its stake in Vir Biotechnology by 0.7% during the first quarter. Principal Financial Group Inc. now owns 40,098 shares of the company's stock worth $2,056,000 after acquiring an additional 287 shares in the last quarter. Quantbot Technologies LP raised its stake in Vir Biotechnology by 250.0% during the first quarter. Quantbot Technologies LP now owns 700 shares of the company's stock worth $35,000 after acquiring an additional 500 shares in the last quarter. State of Wisconsin Investment Board raised its stake in Vir Biotechnology by 1.6% during the fourth quarter. State of Wisconsin Investment Board now owns 75,500 shares of the company's stock worth $2,022,000 after acquiring an additional 1,200 shares in the last quarter. Finally, Profund Advisors LLC raised its stake in Vir Biotechnology by 10.6% during the fourth quarter. Profund Advisors LLC now owns 14,379 shares of the company's stock worth $385,000 after acquiring an additional 1,377 shares in the last quarter. 59.49% of the stock is owned by institutional investors and hedge funds.
Vir Biotechnology Company Profile
Vir Biotechnology, Inc, a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis.
See Also: How is net asset value different from market price?
Get a free copy of the Zacks research report on Vir Biotechnology (VIR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: What Is Dividend Yield and How Do You Calculate It?7 Stocks That Still Have Upside For Investors to Buy
It can be fun to invest in some speculative stocks. But it should go without saying that those stocks shouldn’t make up the bulk of your portfolio. In fact, it’s important to find a few good stocks that make up the base of your portfolio. These are momentum stocks that are in a strong uptrend.
One way to find such stocks is to look at the most active stocks (or volume leaders). Shares of these companies are among the most traded or have the highest dollar volume of shares traded in a given trading day.
Any stock may crack this list from time to time (for example, when there’s new news about the company). However, stocks tend to find their way on this list consistently that bear watching. That’s because this list indicates that there is pressure among investors to buy or sell the stock. And that makes an investor’s decision very simple.
And that’s the reason we created this special presentation. The stocks on this list are among the most actively traded stocks on the market today. They also share a similar quality. They are coming off strong years in 2020 and seem to be showing some consolidation for another leg up.
View the "7 Stocks That Still Have Upside For Investors to Buy"